MedStar Georgetown University Hospital in Washington, D.C., has begun patient treatments using the RayStation treatment planning system in combination with Mevion’s Hyperscan pencil beam scanning system. This was the world’s first treatment carried out on the Mevion S250i Proton Therapy System®.
The combination of RayStation and Mevion’s Hyperscan technology enables clinicians at MedStar Georgetown to plan and treat patients with the advantage of very sharp field edges and minimized radiation to critical structures.
RayStation enables the use of advanced IMPT capabilities that are unique to the Hyperscan technology, including multi-leaf collimation with Mevion’s Adaptive Aperture, a proton multi-leaf collimator (pMLC) designed to achieve sharp lateral dose gradients and protect sensitive organs at every energy layer of the treatment.
Johan Löf, CEO of RaySearch, says: “We are very pleased to see this groundbreaking patient treatment at MedStar Georgetown, using RayStation in combination with Mevion’s Hyperscan technology. Proton therapy is an important focus area and RaySearch is committed to supporting all the latest techniques and systems. Together we will ensure that more and more patients can benefit from this high-precision form of treatment.
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
To learn more about RaySearch, go to: www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00